Ask about this productRelated genes to: GABRA4 antibody
- Gene:
- GABRA4 NIH gene
- Name:
- gamma-aminobutyric acid type A receptor alpha4 subunit
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p12
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-15
- Date modifiied:
- 2016-02-04
Related products to: GABRA4 antibody
Related articles to: GABRA4 antibody
- Late-life depression (LLD) is a debilitating condition, characterized by mood disturbance and cognitive decline. Gamma-aminobutyric acidergic (GABAergic) deficits are a hallmark of both aging and depression; however, few studies have examined the GABAergic system in LLD. We hypothesized that there would be significant decrease in peripheral GABA levels and γ-aminobutyric acid type A (GABA-A) receptor subunit expression in individuals with LLD compared to healthy controls (HC). In this study, we measured plasma GABA levels and the mRNA expression of four GABA-A receptor subunits (GABRA1, GABRA4, GABRA5, and GABRR2) in peripheral blood mononuclear cells (PBMCs) from 87 older adults (LLD, n = 46; HC, n = 41). Plasma GABA levels were quantified using enzyme-linked immunosorbent assay (ELISA), and receptor subunit expression was assessed by quantitative-real time (RT-qPCR). There were no significant differences between LLD and HC in plasma GABA levels or GABA-A receptor subunit expression. In LLD, within-group analyses showed GABRA5, GABRR2, GABRA4, GABRA1 expression were negatively correlated with cognitive performance on the Montreal Cognitive Assessment MoCA scores (ρ = -0.464, p = 0.045, ρ = -0.515, p = 0.041; ρ = -0.414, p = 0.078, and ρ = -0.477, p = 0.062 respectively). This is the first study that investigated GABA-A receptor subunit expression in the periphery of individuals with LLD. Our findings suggest that altered peripheral GABA-A receptor subunit expression, even in the absence of between-group differences, is associated with reduced cognitive function in LLD. - Source: PubMed
Publication date: 2026/05/03
Rezaei SaraSibille EtienneVoineskos DaphneRajji Tarek KNikolova Yuliya SDiniz Breno SVieira Erica L - Radiotherapy often causes severe and irreversible neural damage, including cognitive impairment and depression-like behaviors. Current mitigants are limited, with single-target molecules being ineffective and nanomedicines posing complexity and toxicity risks. Dragon's Blood (DB), a nontoxic, brown-red resin extracted from (Lour.) (S. C. Chen, China), possesses diverse pharmacological properties. Extensive studies demonstrated that the compounds in DB exhibit multiple therapeutic effects, including cardiovascular protection, promotion of blood circulation, and anti-inflammatory effect. Herein, DB's neuronal radiation mitigation effect and mechanism were investigated. In a whole-brain irradiation rat model, DB administration significantly alleviated radiation-induced anhedonia-like behavior, normalized calcium dyshomeostasis, restored mitochondrial membrane potential, mitigated dendritic spine loss, suppressed neuroinflammation (IL-1β and TNF-α), and preserved hippocampal cytoarchitecture. Brain tissue proteomics revealed 23 DB-modulated KEGG pathways, encompassing the glutamatergic/GABAergic synapse, synaptic plasticity, addiction-related pathways, calcium/cAMP signaling, and hormonal regulation. Ensemble analysis integrating proteomics, WGCNA, machine learning, and PPI pinpointed 24 DB radiation mitigation-related proteins. Among these, eight targets (Grin1, Gabra4, Grm2, Grm3, Grm7, Prkcb, Shank3, and Pak7) functioning via ligand-target interactions were dysregulated by radiation and restored by DB. Molecular docking identified three DB ingredients (socotrin-4'-ol, cinnabarone, and 2'-methoxysocotrin-5'-ol) interacted with all eight targets. Plasma proteomics further revealed radiation mitigation-related brain-enriched proteins (Mib1, Gucy1b1, Fkbp1a, Synj1, and Clasp2). PPI between these 5 plasma proteins and 24 brain proteins reveals DB's multitarget radiation mitigation effect on neurotransmission and synaptic regulation, neuroplasticity, and signaling transduction and cellular response. This work nominated DB and its key constituents as promising candidates for mitigating radiotherapy-induced neural injury. - Source: PubMed
Publication date: 2025/11/25
Li BoyangHan ChuZhang HanLi Bo - GABA receptors are present in hindbrain and spinal cord networks, playing a pivotal role in regulating locomotion. In this study, we demonstrate that mutations in the gene, which encodes the α4 subunit of GABA receptors, result in increased swim velocity of larval zebrafish. We also show that this gene is selectively expressed within spinal cord cerebrospinal fluid contacting neurons (CSF-cNs). Given the significance of these neurons in modulating locomotion, our findings support a model in which compromised α4 function leads to an increase in CSF-cN activity, causing a subtle, hyperactive swimming phenotype. - Source: PubMed
Publication date: 2025/12/01
Barnaby WayneO'Malley SydneyDownes Gerald B - Gamma-aminobutyric acid (GABA) supplements are increasingly marketed for promoting growth, yet the genetic influence of GABA receptor subtypes on human height remains unexplored. This Mendelian randomization (MR) study aimed to investigate the causal relationships between genetically predicted plasma levels of 2 GABA receptor subtypes (GABRA4 and GABRB2), and height-related outcomes, including body height (BH), idiopathic short stature (ISS), and constitutional tall stature (CTS). This study employed a two-sample MR approach to assess the causal effect of GABA receptor subtypes, specifically GABRA4 and GABRB2, on height-related traits. Genetic instruments for GABRA4 and GABRB2 were obtained from the UK Biobank Pharma Proteomics Project and INTERVAL study. Outcome data, including BH, ISS, and CTS, were sourced from large-scale genome-wide association studies, including datasets from the FINNGEN study, European Bioinformatics Institute (EBI), and the GIANT Consortium. The inverse variance-weighted method was employed as the primary analytical approach to estimate the causal effects. Sensitivity analyses included MR-Egger regression and the weighted median method to assess for pleiotropy and ensure robustness. Additionally, the MR-PRESSO method was applied to identify and exclude outlier SNPs with potential horizontal pleiotropy, further enhancing the reliability of the causal estimates. Our MR analysis revealed no significant associations between genetically predicted GABRA4 and height-related outcomes after Benjamini-Hochberg correction. In contrast, GABRB2 was positively associated with BH in the EBI dataset (β = 0.0203; P = 1.737e-05), but this association was not replicated in the other datasets. No significant associations were observed for GABRB2 with ISS (OR = 0.82, P = .165) or CTS (OR = 1.47, P = .259). Sensitivity analyses did not suggest any pleiotropic effects. Our MR analysis did not reveal significant causal relationships between GABRA4 or GABRB2 and height-related outcomes, such as BH, ISS, and CTS. To the best of our knowledge, this is the first study to explore the GABA receptor subtypes on human height. This novel approach provides important evidence refuting any direct association between these receptors and human height, filling a critical gap in the existing literature. - Source: PubMed
Chen LianhuiZeng ZhenzhongWu MinHu XiaohaoWang Yongfen - This study investigated miR-7b's regulatory role in the nucleus accumbens (NAc) and its interaction with gamma-aminobutyric acid A receptor alpha 4 (GABRA4) during cue-induced heroin-seeking reinstatement. - Source: PubMed
Publication date: 2025/11/01
Wu TingtingXu WenjinLin ZiXu ZeminHong QingxiaoChen WeishengXie XiaohuFu DanLai MiaojunZhou WenhuaLiu Huifen